

## **N0577: Phase III Intergroup Study of Radiotherapy versus Temozolomide alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma**

### *Fast Facts*

#### **Provided Drug: Temozolomide**

#### **Pre-registration Inclusion Criteria**

1. Willing to submit tissue samples for mandatory central pathology review submission (see Section 17.2) and deletion status determination (see Section 17.51). It should be initiated as soon after surgery as possible.

#### **Inclusion Criteria**

1.  $\geq 18$  years of age.
2. Newly diagnosed and  $\leq 3$  months from surgical diagnosis.
3. Histological confirmation of anaplastic glioma (oligodendroglioma, mixed, or astrocytoma [WHO grade III]), as determined by pre-registration central pathology review, and tumor is also co-deleted for 1p and 19q. NOTE: Mixed gliomas are eligible, regardless of the degree of astrocytic or oligodendrocytic predominance, as long as the tumor is also co-deleted for 1p and 19q.
4. Surgery  $\geq 2$  weeks prior to registration must have recovered from the effects of surgery.
5. The following laboratory values obtained  $\leq 21$  days prior to registration.
  - a. ANC  $\geq 1500$
  - b. PLT  $\geq 100,000$
  - c. Hgb  $> 9.0$  g/dL
  - d. Total bilirubin  $\leq 1.5$  x UNL
  - e. SGOT (AST)  $\leq 3$  x UNL
  - f. Creatinine  $\leq 1.5$  x ULN
6. Negative pregnancy test done  $\leq 7$  days prior to registration, for women of childbearing potential only.
7. Willing and able to complete neurocognitive examination without assistance and the QOL by themselves or with assistance (see Section 4.4).
8. ECOG performance status (PS) of 0, 1 or 2 (Appendix II).
9. Provide informed written consent.
10. Patient willing to provide tissue samples for translation research purposes (see Sections 6.14, 17.3, and 17.52-17.53).


#### **Exclusion Criteria**

1. Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:
  - a. Pregnant women
  - b. Nursing women
  - c. Men or women of childbearing potential who are unwilling to employ adequate contraception
2. Received any prior surgery, radiotherapy or chemotherapy for any CNS neoplasm (hormones, vitamins and growth factors are not considered chemotherapy for the purposes of this study).
3. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
4. Concomitant serious immuno-compromised status (other than that related to concomitant steroids).
5. Active uncontrolled systemic infection or HIV.
6. Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm.
7. Active other malignancy, excepting non-melanotic skin cancer or carcinoma-in-situ of the cervix. NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer.
8. History of myocardial infarction  $\leq 6$  months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.

9. Recent history of hepatitis infection or treating physician determined that the patient would be at significant risk of reactivation of hepatitis.

#### Pre-Study Parameters

1. Pathology review and determination of deletion status
2. Radiation Oncology consult
3. History and exam, weight, performance status, Height, Neuro history and exam
4. Pregnancy test (if applicable)
5. Hematology group; ANC, PLT, Hgb
6. Chemistry group: SGOT [AST], alk phos, T. bili, creatinine, CA, phos, glucose, NA, K
7. Head MRI with contrast or CT with contrast
8. Adverse event assessment
9. Recording of steroid dose
10. Patient Medication Diary
11. Optional research blood draw
12. Mandatory research tissue
13. Neurocognitive/QOL Questionnaire Booklets



Arm A: Cycle = 10-12 weeks (depends on whether or not the patient takes the full 6-week rest period)

Arm B: \* Cycle 1 length = 10 weeks  
 \*\* Cycles 2-7 length = 4 weeks  
 † Option to extend to 12 cycles (cycle = 4 weeks)

Arm C: Cycle = 4 weeks